Cytek Biosciences Statistics
Share Statistics
Cytek Biosciences has 126.66M
shares outstanding. The number of shares has increased by -2.42%
in one year.
| Shares Outstanding | 126.66M |
| Shares Change (YoY) | -2.42% |
| Shares Change (QoQ) | -0.55% |
| Owned by Institutions (%) | 58.96% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 928 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 4.19M, so 3.29% of the outstanding
shares have been sold short.
| Short Interest | 4.19M |
| Short % of Shares Out | 3.29% |
| Short % of Float | 4.27% |
| Short Ratio (days to cover) | 7.15 |
Valuation Ratios
The PE ratio is -140.81 and the forward
PE ratio is -49.5.
Cytek Biosciences's PEG ratio is
2.89.
| PE Ratio | -140.81 |
| Forward PE | -49.5 |
| PS Ratio | 4.23 |
| Forward PS | 1 |
| PB Ratio | 2.14 |
| P/FCF Ratio | 38.79 |
| PEG Ratio | 2.89 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytek Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.86,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.86 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -1.7 |
| Debt / FCF | 0.78 |
| Interest Coverage | -3.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $302,342.38 |
| Profits Per Employee | $-9,079.94 |
| Employee Count | 663 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | 320K |
| Effective Tax Rate | -5.61% |
Stock Price Statistics
The stock price has increased by -58.61% in the
last 52 weeks. The beta is 1.42, so Cytek Biosciences's
price volatility has been higher than the market average.
| Beta | 1.42 |
| 52-Week Price Change | -58.61% |
| 50-Day Moving Average | 3.64 |
| 200-Day Moving Average | 5.15 |
| Relative Strength Index (RSI) | 22.15 |
| Average Volume (20 Days) | 872,480 |
Income Statement
In the last 12 months, Cytek Biosciences had revenue of 200.45M
and earned -6.02M
in profits. Earnings per share was -0.05.
| Revenue | 200.45M |
| Gross Profit | 111.11M |
| Operating Income | -20.52M |
| Net Income | -6.02M |
| EBITDA | -10.03M |
| EBIT | -20.52M |
| Earnings Per Share (EPS) | -0.05 |
Full Income StatementBalance Sheet
The company has 98.72M in cash and 17.02M in
debt, giving a net cash position of 81.7M.
| Cash & Cash Equivalents | 98.72M |
| Total Debt | 17.02M |
| Net Cash | 81.7M |
| Retained Earnings | -35.2M |
| Total Assets | 482.6M |
| Working Capital | 312.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 25.38M
and capital expenditures -3.52M, giving a free cash flow of 21.85M.
| Operating Cash Flow | 25.38M |
| Capital Expenditures | -3.52M |
| Free Cash Flow | 21.85M |
| FCF Per Share | 0.17 |
Full Cash Flow StatementMargins
Gross margin is 55.43%, with operating and profit margins of -10.24% and -3%.
| Gross Margin | 55.43% |
| Operating Margin | -10.24% |
| Pretax Margin | -2.84% |
| Profit Margin | -3% |
| EBITDA Margin | -5.01% |
| EBIT Margin | -10.24% |
| FCF Margin | 10.9% |
